Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

James J. Lee, MD, PhD
Published: Thursday, Jun 25, 2015



James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer. 

About 5% to 10% of metastatic colorectal cancers carry a very unique mutation known as mismatched repair, says Lee.

Colorectal cancer patients that have mismatched repair have a higher chance of their cancer growing and spreading.

Pembrolizumab has the potential to activate the immune system and overcome mismatched repair, says Lee.



James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer. 

About 5% to 10% of metastatic colorectal cancers carry a very unique mutation known as mismatched repair, says Lee.

Colorectal cancer patients that have mismatched repair have a higher chance of their cancer growing and spreading.

Pembrolizumab has the potential to activate the immune system and overcome mismatched repair, says Lee.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x